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Human platelets that had been prelabelled with pzP]Pl were stimulated with trombin in the presence or absence of neomycin, prostaglandin E, 
(PGE,) or chlorpromazine. The content of p’P]P, in phosphatidylinositol 4-phosphate, phosphatidylinositol 4,5bisphosphate and phosphatidic 
acid (PA) were determined. The data demonstrate that PGE, and chlorpromazine but not neomycin interfere with the tight metabolic relationship 
that exists between the inositol phospholipids and PA in thrombin-stimulated platelets [(1989) Biochem. J. 263, 6216241. Our results therefore 
indicate that neomycin does not inhibit signal transduction in intact platelets at the level of the inositol phospholipid metabolism. 
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1. INTRODUCTION 
Receptor-mediated increase in the turnover of the in- 
ositol phospholipids is recognized as a major 
transmembrane signal-processing mechanism (reviewed 
in [ 11). The activation of the phosphoinositide-specific 
phosphodiesterase (PLC) leads to the formation of in- 
ositol 1,4,5_trisphosphate and diacylglycerol which 
mobilizes intracellular Ca2+ and activates protein 
kinase C, respectively. 
Human platelets constitute a suitable model system 
to study stimulus-response coupling in general and 
agonist-induced enhancement of polyphosphoinositide 
(PPI) metabolism in particular. In a recent article [2] 
we demonstrated that receptor-mediated activation of 
the PPI cycle in platelets is under tight metabolic con- 
trol. The relationship between the degree of PLC ac- 
tivation (measured as [32P]PA accumulation) and the 
32P-radioactivity in PIP and PIP2 therefore represents 
a tool to see whether or not a platelet inhibitor interacts 
with the specific steps in the inositol phospholipid 
metabolism 121. Neomycin, chlorpromazine and pro- 
staglandin El (PGEr) are commonly used inhibitors of 
platelet activation which are all believed to interfere 
with the platelet signal processing mechanisms [3-51. 
Although under continuous debate, neomycin and 
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chlorpromazine have been thought primarily to in- 
terfere with the inositol phospholipid metabolism 
[3,4,6-81 whereas PGEi has been demonstrated to in- 
hibit platelet activation through elevation of the CAMP 
level 151. 
In this study we use the tight metabolic relationship 
between the polyphosphoinositides and PA to evaluate 
whether neomycin, chlorpromazine and PGEi 
specifically interfere with the thrombin-induced 
changes in inositol phospholipid metabolism. 
2. MATERIALS AND METHODS 
2.1. Materials 
Neomycin sulfate, PGEt, theophylline, and chlorpromazine were 
obtained from Sigma, “P-orthophosphate (carrier-free) from Amer- 
sham and thrombin (bovine) from Hoffmann-La Roche. The sulfate 
of the neomycin sulfate preparation was exchanged with chloride as 
described in [9]. 
2.2. Platelet isolation, labeliing and incubation 
Platelet-rich plasma was prepared from ACD-anticoagulated 
human blood as previously described [lo], and incubated with [“PIPi 
(0.1 mCi/ml, 60 min, 37’C). The cells were subsequently gel-filtered 
into a nominally Ca*+- and phosphate-free Tyrode’s solution [lo]. 
The final platelet concentration was standardized at 3.5 x lOs/ml. 
The experiments were performed at 37°C and neomycin, chlor- 
promazine or PGEt plus theophylline were added 90 s before the cells 
were exposed to thrombin. To increase the inhibitory effect of PGEr, 
the phosphodiesterase inhibitor theophylline (0.5 mM, final concen- 
tration) was always added together with the prostaglandin. 
2.3. Phospholipid extraction and chromatography 
After 90 s of thrombin stimulation, 0.5 ml of platelet suspension 
was withdrawn and mixed with 2 ml of chloroform/methanol/cone. 
HCl (20 : 40 : 1, by vol.; O’C). The lipids were extracted as previously 
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described and subsequently separated by thin-layer chromatography 
in chloroform/methanol/2OYo methylamine (60 : 36 : 10, by vol.) [lo]. 
The inositol lipids were visualized by overnight radioautography and 
scraped off the plates for determination of radioactivity by liquid 
scintillation counting. 
3. RESULTS AND DISCUSSION 
In a previous communication [2] we demonstrated 
that the steady state levels of PIP and PIP2 correspond 
tightly to the degree of activation of the PPI-specific 
phosphodiesterase (measured as appearance of 
[32P]PA) irrespective of the agonist used. Hence, in- 
hibitors of platelet activation which act on specific 
steps in the metabolism of the inositol phospholipids 
should be expected to interfere with this metabolic rela- 
tionship between PA, PIP and PIP2. In contrast, 
platelet inhibitors which directly or indirectly affect the 
PLC activation (e.g. receptor occupancy, autocrine 
stimulation) should not interfere with the tight 
metabolic relationship between PA and the inositol 
phospholipids. This was shown for the specific throm- 
bin antagonist hirudin and the cyclooxygenase inhibitor 
aspirin 121. 
In this communication, the effects of the platelet in- 
hibitors PGEi, chlorpromazine and neomycin on 
thrombin-induced changes in inositol phospholipid 
metabolism were tested. The data are plotted as 
[32P]PIP or [32P]PIP~ vs [“P]PA (degree of PLC ac- 
tivation), and the effects of increasing concentrations 
of thrombin alone were always tested vs thrombin plus 
inhibitor. 
The addition of PGEi together with thrombin clearly 
decreased both the formation of PA as well as the levels 
of PIP and PIP2 when compared to thrombin alone 
(Fig. 1). The [32P]PIP/[32P]PA and [32P]PIP2/[32P]PA 
relationships therefore became clearly different from 
the relationships obtained with thrombin alone as well 
as for thrombin plus hirudin [2]. 
Chlorpromazine has previously been shown to affect 
the levels of PIP and PIP2 in unstimulated platelets [3]. 
This is in accordance with the present data that 
demonstrate a 100% increase in PIP and a 20% in- 
crease in PIP2 in the unstimulated cells (Fig. 2). The 
addition of thrombin together with chlorprom~ine 
revealed that the drug markedly enhanced the 
thrombin-induced formation of r3’P]PA and [32P]PIP, 
whereas the formation of [32P]PIP~ was increased at 
low degrees of stimulation and markedly decreased 
when the cells were stimulated to [32P]PA levels of 
500% or above. The [3ZP]PIP/[32P]PA and 
[32P]PIP~/[32P]PA relationships induced by thrombin 
plus chlorprom~ine were therefore considerably dif- 
ferent from the relationships obtained with thrombin 
alone. 
The effects of neomycin are demonstrated in Fig. 3. 
In contrast to the two other platelet inhibitors, the ad- 
[=P]PA radioactivIty (% Of control) 
Fig. 1. Relationship between [32P]PIPz, [32P]PIP and [“PIPA in 
thrombin-stimulated platelets in the absence and presence of PGEt 
plus theophylline. [32P]Pi-prelabelled platelets were stimulated with 
increasing concentrations of thrombin (0.03, 0.05, 0.1, 0.3 and 
0.5 U/ml) with (closed symbols) or without (open symbols) PGEr 
plus theophylline (25 nM and 0.5 mM final concentrations, 
res~tively). The data represent the [3zP]PIP~/[3zP]PA and 
[32P]PIP/]32PJPA relationships obtained for each dose of thrombin 
and are expressed as means f SD of 4 independent determinations. 
dition of neomycin together with thrombin only induc- 
ed a shift to the left of the [32P]PIP/[32P]PA and 
[32P]PIP2/[32P]PA relationships as if only a lower con- 
centration of thrombin were used. When the cells were 
incubated with increasing con~ntrations of neomycin 
before exposure to the highest hrombin concentration, 
the [32P]PIP/[32P]PA and [32P]PIP~/[32P]PA relation- 
ships remained unaltered when compared to the rela- 
tionships obtained with thrombin alone (not shown). 
Hence, the effect of neomycin was similar to the effect 
of the thrombin antagonist hirudin [Z]. 
The present data indicate that PGEr and chlor- 
promazine but not neomycin interfere with specific 
steps in the metabolism of the inositol phospholipids 
upon thrombin stimulation of platelets. PGEi is 
generally believed to inhibit platelet activation by in- 
creasing the level of intracellular CAMP thereby ac- 
tivating CAMP-dependent protein kinase which has 
been shown to inhibit the intracellular calcium 
mobili~tion [5]. However, there is also evidence that 
PGEi affects the kinases and phosphatases involved in 
the metabolism of the inositol phospholipids [11,12] as 
is also supported by this study. The data also support 
a previous report which has shown profound effects of 
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Fig. 2. Relat~o~hip between f’lZP]PIP2, 13’P]PIP and [‘*P]PA in 
thrombin-stimulated platelets in the absence (open symbols} and 
presence (closed symbols) of chlorpromazine (30pM, final 
concentration). The experiment was performed as explained in the 
legends to Fig. 1 and the data are expressed as means f SD of 4 
independent determinations. 
ch~orproma~ne on inositol phospho~ipid metabolism in 
resting as well as thrombin-stimulated platelets [3]. The 
mechanism of the inhibitory action of the drug on 
platelet responses is presently unknown, 
Neomycin has been shown to bind to the inositol 
phospholipids [6] and it has generally been assumed 
that it inhibits cellular activation by interfering with the 
signal transduction mechanism at the level of these 
phospholipids [4,T,8]. However, recent data from our 
laboratory i3] as well as others f13] have indicated that 
the drug interferes with the signal transduction at an 
earlier stage. The drug was demonstrated to affect the 
GTPase in human platelet membranes [ 131, but it is still 
an open question whether the highly polar molecule can 
penetrate the intact plasma membrane. The present 
data show that the drug affects the relationship bet- 
ween the inositol phosphoI~pi~ in a similar way to the 
change induced by simply decreasing the strength of the 
stimulus. Such results were also obtained by the addi- 
tion of the specific thrombin-antagonist hirudin to 
thrombin-stimulated cells [2]. Our results therefore 
strongly suggest hat neomycin does not interfere with 
specific steps in the inositol phosphoi~p~d metabolism, 
(32.P]PA radioaclrvrty (% of control) 
Fig. 3. Relationship between [32P]PIP~, [“PIPIP and [3ZP]PA in 
thrombin-stimulated platelets in the absence (open symbols) and 
presence (closed symbols) of neomycin (2 mM, final concentration). 
The experiment was performed as explained in the legends to Fig. 1 
and the data are expressed as means f SD of 4 independent 
determinations. The thrombin co~~ntra~ons used were 0.03, 0.05, 
O.Og, 0.1, 0.3 and 0.5 U/ml ffinal concentrations). 
but acts to inhibit (directly or indirectly) signal 
transduction in platelets at a level prior to the PLC ac- 
tivation. From other cells it has been demonstrated that 
neomycin inhibits the binding of Herpes Simplex virus 
1 to its cellular receptor 1141. Moreover, the inositol 
phosphol~pids which indeed can be inffuenced by the 
drug IS], have been demonstrated to take part in the 
structure of some surface proteins recognized as recep- 
tors [ 151. We therefore suggest that neomycin interferes 
with the thrombin-receptor interaction in intact 
human platelets. Since neomycin also inhibits platelet 
responses induced by collagen and platelet activating 
factor (PAF) 141, it is possible that the receptors for 
thrombin, collagen and PAF all share the same suscep- 
tibility for the antibiotic. 
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